Imiquimod
- Generic Name
- Imiquimod
- Brand Names
- Aldara, Vyloma, Zyclara
- Drug Type
- Small Molecule
- Chemical Formula
- C14H16N4
- CAS Number
- 99011-02-6
- Unique Ingredient Identifier
- P1QW714R7M
- Background
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and cont...
- Indication
For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
- Associated Conditions
- Actinic Keratoses of the face, Actinic Keratoses of the scalp, Condylomata Acuminata, Herpes Simplex Infections, Molluscum Contagiosum, Superficial Basal Cell Carcinoma
- Associated Therapies
- -
Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV
- Conditions
- Interventions
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- United States Naval Medical Center, San Diego
- Registration Number
- NCT01663558
- Locations
- 🇺🇸
NMCSD, San Diego, California, United States
Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation
- Conditions
- Interventions
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- CONRAD
- Target Recruit Count
- 20
- Registration Number
- NCT01593124
- Locations
- 🇺🇸
Eastern Virginia Medical School CONRAD Clinical Research Center, Norfolk, Virginia, United States
Intradermal Trivalent Influenza Vaccine With Imiquimod
- Conditions
- Interventions
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 93
- Registration Number
- NCT01508884
- Locations
- 🇭🇰
The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 221
- Registration Number
- NCT01453179
- Locations
- 🇩🇪
Medical Department of Otto-von-Guericke-University Magdeburg, University Clinic for Dermatology and Venerology, Magdeburg, Germany
🇦🇹Medical University Vienna, Department for General Dermatology, Vienna, Austria
🇩🇪Medical Practice, Münster, Germany
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
- Conditions
- Interventions
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 31
- Registration Number
- NCT01421017
- Locations
- 🇺🇸
New York University Medical Center, New York, New York, United States
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
- Conditions
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 6
- Registration Number
- NCT01403285
- Locations
- 🇺🇸
Neuro-Oncology Branch of the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma
- Conditions
- Interventions
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 8
- Registration Number
- NCT01400672
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
- First Posted Date
- 2010-12-22
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 4
- Registration Number
- NCT01264731
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- Tennessee Clinical Research Center
- Target Recruit Count
- 21
- Registration Number
- NCT01203878
- Locations
- 🇺🇸
AboutSkin Dermatology and DermSurgery, PC, Englewood, Colorado, United States
🇺🇸Dermatology, Laser & Vein Specialists of the Carolinas, Charlotte, North Carolina, United States
🇺🇸Tennessee Clinical Research Center, Nashville, Tennessee, United States
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
- Conditions
- Interventions
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 8
- Registration Number
- NCT01171469
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.